UK markets closed
  • NIKKEI 225

    27,927.37
    -102.20 (-0.36%)
     
  • HANG SENG

    23,349.38
    -417.31 (-1.76%)
     
  • CRUDE OIL

    69.92
    +3.66 (+5.52%)
     
  • GOLD FUTURES

    1,779.50
    -4.40 (-0.25%)
     
  • DOW

    35,227.03
    +646.95 (+1.87%)
     
  • BTC-GBP

    36,989.09
    +113.77 (+0.31%)
     
  • CMC Crypto 200

    1,270.46
    +10.30 (+0.82%)
     
  • ^IXIC

    15,225.15
    +139.68 (+0.93%)
     
  • ^FTAS

    4,117.60
    +58.28 (+1.44%)
     

PharmaSGP reporting 34% revenue growth and increased profitability in Q3 2021

  • Oops!
    Something went wrong.
    Please try again later.
·6-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DGAP-News: PharmaSGP Holding SE / Key word(s): Preliminary Results/9 Month figures
16.11.2021 / 07:30
The issuer is solely responsible for the content of this announcement.

PharmaSGP reporting 34% revenue growth and increased profitability in Q3 2021


Gräfelfing, November 16, 2021 - While area-wide lockdowns continued to weigh on the markets into the second quarter, a recovery of the OTC markets has been observed since the middle of the year. In this environment, PharmaSGP achieved the strongest quarter in the company's history, posting revenues of € 19.7 million and a 33.8% increase in revenues in the third quarter compared to the prior year (Q3 2020). By comparison with the second quarter of 2021, revenue was boosted by 40.1%. These figures indicate that the growth rate in Q3 2021 is significantly higher than that of the OTC market in Germany with 6% (Q3 2021 vs. Q3 2020). Organic business from the existing portfolio was the main driver of these positive developments. As of September, the first revenues from the acquired portfolio with the brands Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R) contributed to the positive overall development. In the strategically important "Health Brands" category, revenues advanced from € 12.8 million (Q2 2021) to € 18.7 million, which reflects a growth rate of 46.1%.

Viewed over the first nine months of 2021, revenue amounted to € 46.2 million (previous year: € 48.6 million). The development in the first half of 2021, however, especially in the first quarter, was still burdened by the effects of the COVID-19 pandemic. Revenue in the "Health Brands" category - by contrast with the overall OTC market - developed positively in the first nine months of 2021, achieving growth of 2.5% by comparison with the same period of the previous year, reaching a value of € 42.8 million (previous year: € 41.7 million). In the "Beauty Brands" category, which was severely impacted by the pandemic, revenues were down as expected to € 3.4 million in the first nine months of 2021 (previous year: € 6.8 million). In the first nine months of 2021, earnings before interest, tax, depreciation and amortization adjusted for one-time costs and special effects (adjusted EBITDA) amounted to € 13.2 million (previous year: € 15.8 million). This corresponds to an adjusted EBITDA margin (measured against revenues) of 28.7 % (previous year: 32.5 %). In the third quarter of 2021, PharmaSGP was able to realise an adjusted EBITDA margin of 34.2%, a figure well above 30%. In the first nine months of 2021, unadjusted EBITDA amounted to € 12.5 million.

"Our strong organic growth in the third quarter, as well as the return to our usual margin level impressively demonstrates the potential of PharmaSGP's business model. We are very pleased that we are now back on the growth course with our business development," as CEO Natalie Weigand commented.

"Going forward, our growth will also benefit strongly from the acquisition of the brand portfolio we took on board end of August," adds Michael Rudolf, CFO of PharmaSGP. "The integration into our platform is proceeding as planned. We perceive significant value creation opportunities in the brands we have acquired, which we can leverage through our platform strategy."

The Executive Board continues to assume that the forecast for the 2021 financial year, which was adjusted in September following the expansion of the product portfolio, will be achieved. With a look to the 2021 financial year, the Management Board now expects revenues of between € 60 million and € 65 million. The adjusted EBITDA margin is expected to rise to between 27 % and 31 % by comparison with the 2020 fiscal year. The further course of the Covid-19 pandemic represents a key factor for the overall development and growth of PharmaSGP in 2021. It is assumed that no renewed negative impact will occur in the second half of 2021 with regard to the European OTC markets relevant for PharmaSGP.

PharmaSGP will publish the 9-month announcement on 30 November 2021, in the 'Publications' section of the company's website ir.pharmasgp.com.
 

OVERVIEW OF PRELIMINARY YEAR-ON-YEAR FIGURES

Group figures (in € million)

9M 2021

9M 2020

Revenues

46.2

48.6

-4.9 %

Adjusted EBITDA

13.2

15.8

-16.1 %

Unadjusted EBITDA

12.5

14.4

-13.0 %

Adjusted EBITDA margin

28.7 %

32.5 %

 

Unadjusted EBITDA margin

27.1 %

29.7 %

 

 

 

 

 

Revenues by regions (in € million)

9M 2021

9M 2020

Germany

31.8

33.7

-5.6 %

Italy

6.3

6.9

-8.8 %

Austria

5.8

5.0

+16.6 %

Other European countries

2.3

3.0

-23.7 %

 

 

 

 

Share of revenues by region

9M 2021

9M 2020

Germany

68.8 %

69.2 %

 

Italy

13.6 %

14.2 %

 

Austria

12.6 %

10.4 %

 

Other European countries

5.0 %

6.2 %

 

 

 

 

 

Revenues by product category (in € million)

9M 2021

9M 2020

Health Brands

42.8

41.7

+2.5 %

Beauty Brands

3.4

6.8

-50.1 %

 

 

 

 

 

 

CONTACT

cometis AG
Claudius Krause
Phone: 49-611-20585528
Email: ir@pharmasgp.com


ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with the focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX(R) for rheumatic pain and Restaxil(R) for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R), thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe.

In 2020, PharmaSGP generated revenues of € 63.2 million at an adjusted EBITDA margin of 26.9 %.

In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, increase PharmaSGP's European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.


16.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

PharmaSGP Holding SE

Lochhamer Schlag 21

82166 Gräfelfing

Germany

E-mail:

ir@pharmasgp.com

Internet:

https://pharmasgp.com

ISIN:

DE000A2P4LJ5

WKN:

A2P4LJ

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich

EQS News ID:

1249193


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting